ISAD 2023 Gdańsk motto: Solidarity in AD

Registration and Abstract submission system will open in mid-February 2023.
Dates and deadlines will be announced via newsletter onlyregister here

Keynote speakers

  • Jiyoung AHN, Seoul (Republic of Korea)
  • Martin BACHMANN, Bern (Switzerland)
  • George du TOIT, London (UK)
  • Ousmane FAYE, Bamako (Mali)
  • Erika JENSEN-JAROLIM, Vienna (Austria)
  • Christian VESTERGAARD, Aarhus (Denmark)
  • Andreas WOLLENBERG, Munich (Germany)
  • Alexander ZINK, Munich (Germany)

To attend virtually or to get all posters…

Please note all sessions will be based on Gdańsk time zone.
Central European Summer Time (CEST) / Poland time (Warsaw) / UTC+2

Solidarity Day
Thursday, August 31, 2023

08:00

Worldwide Solidarity in the Care of AD Patients
Pre-Meeting: Organization of Care in Atopic Dermatitis

Roberto TAKAOKA, São Paulo & Jean-François STALDER, Nantes (OPENED)


➜ program of the pre-meeting & registration (free)

 
12:00 60 min Lunch break
 
13:00

Welcome addresses

13:00
Welcome to Gdańsk

Magdalena TRZECIAK, Gdańsk

13:05
ISAD: past, present, future

Alain TAÏEB, Bordeaux

 
13:20 1. Initiatives at the international level
Chairs: Magdalena TRZECIAK, Roberto TAKAOKA (01h30)
13:20 IL1
Keynote lecture: Atopic dermatitis and teledermatology in Mali

Ousmane FAYE, Bamako

13:40 IL2
Atopic dermatitis in China

Lin MA, Beijing

13:52 IL3
Atopic dermatitis in Australia

John C. SU, Melbourne

14:04 IL4
Phenotypes and endotypes of atopic dermatitis in Chile

Arturo BORZUTZKY, Santiago

14:16 IL5
Atopic dermatitis in Qatar

Martin STEINHOFF, Doha

14:28 IL6
Management of Atopic dermatitis in Madagascar

Fahafahantsoa RAPELANORO RABENJA, Antananarivo

14:40 IL7
Atopic dermatitis in Poland

Magdalena TRZECIAK

14:50
Q&A
 
15:00 2. A multispecialty approach
Chairs: Roman NOWICKI, Peter SCHMID-GRENDELMEIER (01h30)
15:00 IL8
Keynote lecture: AD and food allergy

George du TOIT, London

15:20 IL9
Disease antagonisms in atopic dermatitis between comorbidity and co-protection – implications for therapy

Johannes RING

15:35 IL10
AD and asthma. T2 siblings?

Maciej KUPCZYK, Łódź

15:50 IL11
Microbiota modulation for AD: benefits or hype?

Hanna SZAJEWSKA, Warsaw

16:05 IL12
Feeling well, being well – the brain-skin connection

Wiesław CUBAŁA, Gdańsk

16:20
Q&A
 
16:30 Poster session 1 + 30 min Coffee break [details]
 
17:00 3. Accessibility to drugs in AD
Moderators: José RUIZ-POSTIGO, Alain TAÏEB (01h00)
Summary of the ISAD-WHO pre-meeting

Roundtable format

 
19:00 Opening Ceremony / Welcome reception: Artus Court➜ Check details here
 

On the way to freedom?
Friday, September 1, 2023

08:30 4. Mechanisms of disease & models
Chairs: Kenji KABASHIMA, Martin STEINHOFF
Standard session with free communications
(01h30)
08:30 IL13
Keynote lecture: Reconsidering the farm effect in AD and allergy

Erika JENSEN-JAROLIM, Vienna

08:50 OL1
Acute stress aggravates itch in experimental atopic dermatitis and drives changes in trigeminal ganglion neurons related to neuroinflammation

Sang Eun LEE

09:05 OL2
Filaggrin insufficiency affects long-distant communication mediated by keratinocyte-derived small extracellular vesicles and promotes allergic inflammation

Danuta GUTOWSKA-OWSIAK

09:20 OL3
The immune response of sensitzed AD patients to house dust mite comprises IL-17, capable of inducing a cytokine response from keratinocyes

Lennart M. ROESNER

09:35 OL4
Characterization of IL-13 producing cells in moderate to severe adult Atopic dermatitis patient’s skin

Gaurav ISOLA

09:50
Q&A
 
10:00 Poster session 2 + 30 min Coffee break [details]
 
10:30 5. Topical treatment and phototherapy: an endangered regimen?
Chairs: Michael J. CORK, John C. SU
Standard session with free communications
(01h30)
10:30 IL14
Keynote lecture: The evolution of topical treatment of Atopic dermatitis

Andreas WOLLENBERG, Munich

10:50 OL5
Association of cumulative topical corticosteroid exposure with fractures among older adults: a case-control study

Aaron M. DRUCKER

11:05 OL6
Association between the use of topical calcineurin inhibitors and the risk of cancer among patients with atopic dermatitis: A nationwide, population-based, retrospective cohort study

Chia-Yu CHU

11:20 OL7
Early relief of clinical symptoms and the improvement during the maintenance period of childhood atopic dermatitis: A multicenter clinical study of crisaborole ointment

Shan WANG

11:35 OL8
The effectiveness of antibacterial therapeutic clothing compared with to non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis: preliminary results from a pragmatic randomized controlled trial

Aviël RAGAMIN

11:50
Q&A
 
12:00 6. Global Corporate Pharma perspectives
Chairs: Ncoza DLOVA, Peter SCHMID-GRENDELMEIER
Scientific session programmed by corporate members
(30 min.)
Titles of communications to be announced
 
12:30 7. Highlighting new drugs in real life
Chairs: Ncoza DLOVA, Alan D. IRVINE (30 min.)
12:30 OL11
Real-world data of abrocitinib treatment in patients with atopic dermatitis: results from the BioDay registry

Esmé KAMPHUIS

12:40 OL12
Efficacy and safety of upadacitinib for atopic dermatitis in dupilumab non-responders: a multicenter retrospective study

Jensen YEUNG

12:50 OL13
Baricitinib as a Useful Treatment for Mild-to-Moderate Atopic Dermatitis: A Real-World Experience

Narang HONG

 
13:00 60 min Lunch break
 
14:00 8. AD comorbidities: facts, fancy, fiction
Chairs: Magdalena CZARNECKA-OPERACZ, Mette DELEURAN (01h30)
14:00 IL15
Keynote lecture: AD comorbidities: the EBM of today

Jiyoung AHN, Seoul

14:20 IL16
Coexistence of AD and alopecia areata. Impact on therapeutic decisions

Lidia RUDNICKA, Warsaw

14:35 OL14
Atopic dermatitis is associated with increased risk of onset of cardiovascular diseases: a retrospective analysis based on electronic records from the global collaborative network

Henner ZIRPEL

14:50 OL15
Impact of COVID-19 and COVID-19 vaccination on atopic dermatitis patients: Lessons from the SECURE-AD Patient Survey

Bouchra EZZAMOURI

15:05 OL16
Atopic Dermatitis as a Risk Factor for Post-arthroplasty Surgical Site Infections in Older Adults

Yagmur HALEZEROGLU

15:20
Q&A
 
15:30 Poster session 3 + 30 min Coffee break [details]
 
16:00 9. Systemic strategies for children & adults
Moderators: Amy S. PALLER, Thomas BIEBER (01h30)
Short-term or long-term treatment? when & how to start? Early systemic intervention in children?

Roundtable format, discussants: Michele RAMIEN, Carlo GELMETTI, Kenji KABASHIMA, Kyu Han KIM, John C. SU, Antonio TORRELO, Andreas WOLLENBERG

 
17:30 10. Travel grants and ISAD fellowships
Chairs: Johannes RING, Jacek SZEPIETOWSKI
Communications from grant awardees
(01h00)
17:30 OL17
Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis

Catherine DROITCOURT

17:45 OL18
The effect of single nucleotide polymorphism in COL23A1 gene on increased HSV-1 susceptibility of human macrophages

Mikhail MAKMATOV-RYS

18:00 OL19
Quality of life in patients with atopic dermatitis in Bamako

Lamissa CISSE

18:15 OL20
The Dynamics of Skin Microbiome during Treatment in Patients with Atopic Dermatitis

Alpana MOHTA

18:30
Q&A
 
20:00 Gala Dinner: Teatr Szekspirowski (Gdańsk Shakespeare Theatre) (03h00)
➜ Check details here
 

Breakthroughs and challenges day
Saturday, September 2, 2023

08:30 11. Challenges in AD management
Chairs: Małgorzata SOKOŁOWSKA-WOJDYŁO, Sébastien BARBAROT
Standard session with free communications
(01h30)
08:30 IL17
Keynote lecture: Treatment of AD in pregnancy and lactation period

Christian VESTERGAARD, Åarhus

08:50 IL18
Safety of atopic dermatitis therapies in the context of cutaneous lymphomas’ risk

Małgorzata SOKOŁOWSKA-WOJDYŁO, Gdańsk

09:05 OL21
The concept of disease modification in atopic dermatitis: scientific and regulatory challenges for drug discovery and development

Thomas BIEBER

09:20 OL22
Treatment response to continuous Dupilumab over time: a retrospective observational study of 123 adult atopic dermatitis patients with changes in blood biomarkers for more than 2 years

Haruna MATSUDA-HIROSE

09:35 OL23
Molecular profiling of allergen-antibody IgE and the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites

Martyna MIODOŃSKA

09:50
Q&A
 
10:00 Poster session 4 + 30 min Coffee break [details]
 
10:30 12. Therapeutic and technology innovation 1
Chairs: Adam REICH, Thomas WERFEL
Standard session with free communications
(01h30)
10:30 IL19
Keynote lecture: Vaccination against allergies

Martin BACHMANN, Bern

10:50 OL24
The skin microbiome prior to the development of childhood atopic dermatitis

Anne-Sofie HALLING

11:05 OL25
Dupilumab provides sustained effectiveness in patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice Bioday Registry

Junfen ZHANG

11:20 OL26
Real-Life Case-Series Experience with Tralokinumab in patients with severe atopic dermatitis

Francesca CAROPPO

11:35 OL27
In pursuit of meaningful change: enhancing interpretability of the Recap of atopic eczema (RECAP) instrument

Arabella BAKER

11:50
Q&A
 
12:00 13. Therapeutic and technology innovation 2
Chairs: Joanna NARBUTT, DirkJan HIJNEN
Standard session with free communications
(01h30)
12:00 IL20
Keynote lecture: Internet data mining and AD

Alexander ZINK, Munich

12:20 OL28
A Large Language Model Artificial Intelligence for Patient Queries in Atopic Dermatitis

Pranvera SULEJMANI

12:35 OL29
McGill Adult Atopic Dermatitis Digital Outcomes (MAADDO) Study: Development and User Testing of the EczemaQ Mobile Application

Kaiyang LI

12:50 OL30
Real-World Experience on Efficacy and Safety of Upadacitinib in Patients with Atopic Dermaitits in Korea

Jiyoung AHN

13:05 OL31
The Impact of Baseline Disease Severity on Short-Term Efficacy of Abrocitinib and Dupilumab in Patients With Atopic Dermatitis: A Post Hoc Analysis of the Phase 3 JADE COMPARE Trial

Zakiya P. RICE

13:20
Q&A
 
13:30   Closing ceremony (30 min)
Closing remarks

Magdalena TRZECIAK & Alain TAÏEB

Next Rajka Symposium: Doha, Qatar

Martin STEINHOFF

 
14:00 Farewell lunch

Honour Patronages:


ISAD 2023